Retinal disease drug developer Gyroscope Therapeutics has raised series C funding from investors including Fosun Pharma.
Gyroscope Therapeutics, a UK-based developer of treatments for retinal disease, secured $148m today in a series C round backed by Fosun Pharma, the pharmaceutical subsidiary of diversified conglomerate Fosun.
The round was led by Forbion’s Growth Opportunities Fund and included life sciences investment firm Syncona, Cambridge Innovation Capital (CIC), Sofinnova Investments, Tetragon Financial Group and an unnamed healthcare fund. Syncona supplied $42.3m and now owns a 54% stake in the company.
Established by Syncona and tech transfer office Cambridge Enterprise…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
